Teva and Active Biotech not giving up on EU-spurned MS treatment

It's confirmed: The EU's Committee for Medicinal Products for Human Use (CHMP) is sticking to its opinion to recommend against approval of Teva ($TEVA) and Active Biotech's ($ACTI) MS drug Nerventra. But the companies aren't giving up, announcing Friday that they remain committed to the clinical development program and plan to evaluate CHMP's feedback before they plot out their next steps. With Teva staring generic competition in the face for its MS blockbuster Copaxone, it needs to pursue all avenues. Release | More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.